galinpepimut-s
Generic: GPS·Code: GPS
galinpepimut-s: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | Phase 3 |
Clinical Trials (1)
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Frequently asked questions
Who is developing galinpepimut-s?
galinpepimut-s is being developed by SELLAS Life Sciences Group, Inc..
How many clinical trials involve galinpepimut-s?
BioSniper tracks 1 clinical trial involving galinpepimut-s.
Get deeper analysis on galinpepimut-s
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis